Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could one radiation dose be enough? new study aims to cut treatment time for breast cancer patients

NCT ID NCT06885671

Symptom relief Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study tests if a single, targeted radiation treatment works as well as the usual five treatments for early-stage breast cancer after lumpectomy. The goal is to make treatment easier for patients who live far from cancer centers. Sixty women aged 40 and older with small, early-stage breast tumors will be randomly assigned to receive either one or five radiation sessions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants age 40 or older * Able to provide informed consent * pTis-2 pN0 cM0 breast cancer, with tumor size \<3 cm as per provincial guidelines * Able to complete electronic or paper entry of participant reported outcomes independently or with assistance from caregiver/family/friend/research staff * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * A history and physical (clinical breast) examination, including ECOG performance status, performed within 8 weeks prior to enrollment. * Participant is judged able to: * Maintain a stable position during therapy * Tolerate immobilization device(s) that may be required to deliver PBI safely * Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date Exclusion Criteria: * History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years. * Uncontrolled concurrent malignant cancer * Seroma not visible * Ipsilateral implanted cardiac device * Prior radiotherapy requiring summation for planning. * Requirement for a radiation boost (as determined by the treating investigator) * Positive surgical margins * Surgical cavities lacking clear delineation (surgical clips are not required but may assist in target delineation) * Known germline BRCA1/2 mutation. * Serious medical comorbidities precluding radiotherapy (e.g., connective tissue disorders such as lupus or scleroderma) * Pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer early stage breast cancer (stage 1-3) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer early stage breast cancer (stage 1-3)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BC Cancer - Prince George

    RECRUITING

    Prince George, British Columbia, V2M 7E9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.